These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 20451251)

  • 21. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
    Gattermann N; Finelli C; Della Porta M; Fenaux P; Stadler M; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Marcellari A; Roubert B; Rose C
    Haematologica; 2012 Sep; 97(9):1364-71. PubMed ID: 22419577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
    Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
    Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
    Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
    Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
    Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C; Roccabruna E; D'Ascola DG
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A; Stone RM
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract]   [Full Text] [Related]  

  • 35. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
    Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
    Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deferasirox: an update.
    Porter JB
    Hemoglobin; 2009; 33 Suppl 1():S70-5. PubMed ID: 20001635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
    Porter J; Galanello R; Saglio G; Neufeld EJ; Vichinsky E; Cappellini MD; Olivieri N; Piga A; Cunningham MJ; Soulières D; Gattermann N; Tchernia G; Maertens J; Giardina P; Kwiatkowski J; Quarta G; Jeng M; Forni GL; Stadler M; Cario H; Debusscher L; Della Porta M; Cazzola M; Greenberg P; Alimena G; Rabault B; Gathmann I; Ford JM; Alberti D; Rose C
    Eur J Haematol; 2008 Feb; 80(2):168-76. PubMed ID: 18028431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
    Chueh HW; Sung KW; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
    Pediatr Blood Cancer; 2012 Mar; 58(3):441-7. PubMed ID: 21638755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.